|
Summary Information: Akero Therapeutics Inc. Common Stock NASDAQ:AKRO |
  admin@troach.net |
Our Main Pages Stocks.TRoach.Net TRoach.Org TRoach.Net |
_Description: Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, EFX, an engineered Fc-FGF21 fusion protein, is currently being evaluated in Phase 2 clinical trials as a potential treatment for NASH. Akero is headquartered in South San Francisco.
__The following are links to various summary and news pages for __Akero Therapeutics Inc. Common Stock [ AKRO ]. __Note: Some Links might not have information for the company. |
|